Triptorelin Pamoate

DRUG9 trials

Sponsors

European Organisation For Research And Treatment Of Cancer, Children's Hospital Medical Center, Cincinnati, University of Washington, Watson Pharmaceuticals, University of California, San Francisco

Conditions

Cancer of ProstateCentral Precocious PubertyEstrogen Receptor-positive Breast CancerHER2-negative Breast CancerHematopoietic and Lymphatic System NeoplasmHormone Naive Prostate CancerMalignant Solid NeoplasmProgesterone Receptor-positive Breast Cancer

Phase 2

Triptorelin for Ovary Protection in Childhood Onset Lupus

CompletedNCT00124514

Children's Hospital Medical Center, CincinnatiSystemic Lupus Erythematosus

Start: 2003-06-30End: 2014-03-31Updated: 2021-01-05

Triptorelin for Ovary Protection in Childhood Onset Lupus

CompletedNCT00124514

Children's Hospital Medical Center, CincinnatiSystemic Lupus Erythematosus

Start: 2003-06-30End: 2014-03-31Updated: 2021-01-05

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

TerminatedNCT00194792

University of WashingtonEstrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer +3

Start: 2005-08-31End: 2011-07-31Updated: 2017-07-11

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

TerminatedNCT02168062

University of California, San FranciscoProstate Adenocarcinoma

Start: 2014-06-16End: 2018-05-22Updated: 2020-07-23

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

RecruitingNCT03899077

Cancer Research AntwerpCancer of Prostate

Start: 2019-04-05End: 2025-12-31Target: 202Updated: 2024-02-07

EORTC-1532-GUCG: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer.

Active, not recruitingCTIS2024-510840-30-00

European Organisation For Research And Treatment Of CancerHormone Naive Prostate Cancer

Start: 2017-12-01Target: 169Updated: 2025-05-26

Phase 3

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

CompletedNCT05029622

IpsenCentral Precocious Puberty

Start: 2021-08-10End: 2023-02-13Updated: 2025-02-19

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

RecruitingNCT06513962

Children's Oncology GroupHematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

Start: 2025-02-27End: 2029-10-30Target: 60Updated: 2026-02-24

Phase 4

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

CompletedNCT01161563

Watson PharmaceuticalsProstate Cancer

Start: 2010-07-31End: 2011-04-30Updated: 2013-09-06

Unknown Phase

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Active, not recruitingNCT02346253

Stanford UniversityProstate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer +2

Start: 2015-01-13End: 2026-05-17Updated: 2025-04-03

Related Papers

A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.

2024-10-16

Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy

Future Oncology2020-05-01

A multidisciplinary team-based approach to mitigate the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study.

Journal of Clinical Oncology2019-03-01

High-resolution peripheral quantitative computed tomography (HR-pQCT) to detect compartmental bone loss on androgen deprivation therapy (ADT): A feasibility study.

Journal of Clinical Oncology2017-02-20

A multidisciplinary clinic to mitigate the toxicity of therapy for newly diagnosed metastatic prostate cancer undergoing chemohormonal therapy: A feasibility study.

Journal of Clinical Oncology2017-02-10

Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.

2013-09-013 citations